Regulation of Th2 responses by Lactococcus lactis subsp. cremoris YRC3780 alleviates DNCB-induced atopic dermatitis in the mouse model
2022
Wang, Rong | Nakajima-Adachi, Haruyo | Wang, Yimei | Zhou, Yingyu | Gu, Wenting | Hiraide, Erika | Morinaga, Mamiko | Nakagawa, Ryogo | Nakamura, Shōtarō | Takano, Tomohiro | Li, Xuyang | Saeki, Mayumi | Kaminuma, Osamu | Hiroi, Takachika | Uchida, Kenji | Motoshima, Hidemasa | Tanokura, Masaru | Miyakawa, Takuya | Hachimura, S. (Satoshi)
Lactococcus lactis subsp. cremoris YRC3780 (L. cremoris YRC3780) was isolated from kefir, and anti-allergic effects have been confirmed in humans. The mechanisms by which L. cremoris YRC3780 affects the Th1/Th2 balance in mice were investigated in vitro, focusing on the intestinal immune response. Simultaneously, a 2,4-dinitrochlorobenzene-induced atopic dermatitis mouse model was used to evaluate the symptom improvement effect of oral administration of L. cremoris YRC3780. The results showed that L. cremoris YRC3780 enhanced IFN-γ and IL-12 production and inhibited IL-4 production from CD4⁺ T cells in the presence of various types of immune cells. Oral administration of L. cremoris YRC3780 attenuated serum total IgE (p < 0.05) and decreased ear thickness (p < 0.05) in the atopic dermatitis model. The examination of cytokine expression suggested that L. cremoris YRC3780 improved AD-like symptoms by inhibiting IL-4 gene expression from Peyer's patches CD4⁺ T cells (p < 0.01) and IL-33 gene expression (p < 0.05) in the draining lymph nodes.
Afficher plus [+] Moins [-]Mots clés AGROVOC
Informations bibliographiques
Cette notice bibliographique a été fournie par National Agricultural Library
Découvrez la collection de ce fournisseur de données dans AGRIS